The Food and Drug Administration approved cabozantinib, or Cabometyx, marketed by Exelixis (EXEL), for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors and well-differentiated extra-pancreatic neuroendocrine tumors, the agency announced.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis to present positive preclinical data across pipeline portfolio at AACR
- Exelixis price target raised to $40 from $38 at RBC Capital
- Wells Fargo downgrades Exelixis, says take profits after rally
- Exelixis downgraded to Equal Weight from Overweight at Wells Fargo
- Exelixis announces final five-year follow-up results from CheckMate -9ER